Phaarmasia Ltd
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
- Market Cap ₹ 32.4 Cr.
- Current Price ₹ 47.4
- High / Low ₹ 64.8 / 24.5
- Stock P/E
- Book Value ₹ 14.6
- Dividend Yield 0.00 %
- ROCE -4.65 %
- ROE -4.93 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.25 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -9.56% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13.85 | 15.16 | 12.30 | 13.68 | 14.33 | 18.97 | 23.97 | 19.93 | 16.20 | 16.88 | 27.42 | 30.59 | 29.29 | |
13.19 | 14.32 | 11.35 | 12.94 | 14.19 | 18.31 | 23.24 | 19.11 | 16.26 | 18.62 | 28.97 | 31.41 | 30.14 | |
Operating Profit | 0.66 | 0.84 | 0.95 | 0.74 | 0.14 | 0.66 | 0.73 | 0.82 | -0.06 | -1.74 | -1.55 | -0.82 | -0.85 |
OPM % | 4.77% | 5.54% | 7.72% | 5.41% | 0.98% | 3.48% | 3.05% | 4.11% | -0.37% | -10.31% | -5.65% | -2.68% | -2.90% |
0.01 | 0.00 | 0.07 | 0.01 | 0.58 | 0.53 | 0.60 | 0.58 | 0.89 | 0.47 | 0.52 | 0.66 | 0.69 | |
Interest | 0.02 | 0.02 | 0.03 | 0.01 | 0.01 | 0.04 | 0.04 | 0.04 | 0.01 | 0.00 | 0.04 | 0.04 | 0.02 |
Depreciation | 0.43 | 0.38 | 0.76 | 0.50 | 0.44 | 0.47 | 0.46 | 0.40 | 0.34 | 0.29 | 0.36 | 0.34 | 0.33 |
Profit before tax | 0.22 | 0.44 | 0.23 | 0.24 | 0.27 | 0.68 | 0.83 | 0.96 | 0.48 | -1.56 | -1.43 | -0.54 | -0.51 |
Tax % | 18.18% | 18.18% | 39.13% | 83.33% | 37.04% | 16.18% | 6.02% | 44.79% | 33.33% | -1.28% | -11.89% | -5.56% | |
0.18 | 0.35 | 0.14 | 0.04 | 0.16 | 0.57 | 0.78 | 0.54 | 0.31 | -1.55 | -1.26 | -0.52 | -0.45 | |
EPS in Rs | 0.26 | 0.51 | 0.21 | 0.06 | 0.23 | 0.83 | 1.14 | 0.79 | 0.45 | -2.27 | -1.85 | -0.76 | -0.66 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 24% |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 59% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 23% |
3 Years: | 10% |
1 Year: | 87% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -4% |
3 Years: | -10% |
Last Year: | -5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 |
Reserves | 0.69 | 0.62 | 6.28 | 5.04 | 4.83 | 5.20 | 5.99 | 6.58 | 6.83 | 5.23 | 3.98 | 3.47 | 3.11 |
0.00 | 0.00 | 0.11 | 0.09 | 0.07 | 0.22 | 0.19 | 0.08 | 0.05 | 0.03 | 0.27 | 0.14 | 0.08 | |
17.26 | 5.91 | 6.17 | 6.74 | 7.81 | 9.67 | 20.25 | 20.11 | 8.20 | 9.12 | 17.34 | 21.01 | 16.87 | |
Total Liabilities | 24.78 | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 26.89 |
11.14 | 10.51 | 15.61 | 14.11 | 13.74 | 14.18 | 13.80 | 13.40 | 13.06 | 12.76 | 12.79 | 12.48 | 12.32 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
13.64 | 2.85 | 3.78 | 4.59 | 5.80 | 7.74 | 19.46 | 20.20 | 8.85 | 8.45 | 15.63 | 18.97 | 14.57 | |
Total Assets | 24.78 | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 26.89 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.09 | 0.16 | 0.48 | 0.28 | -0.08 | 0.88 | 0.06 | 0.08 | 0.25 | -0.18 | 0.65 | 0.11 | |
-0.15 | -0.17 | -0.34 | -0.28 | -0.18 | -0.92 | -0.10 | 0.00 | 0.00 | 0.01 | -0.01 | 0.00 | |
0.00 | 0.00 | 0.12 | 0.16 | -0.02 | 0.08 | 0.04 | -0.11 | -0.02 | 0.00 | -0.16 | -0.16 | |
Net Cash Flow | -0.06 | -0.01 | 0.26 | 0.17 | -0.29 | 0.04 | 0.00 | -0.03 | 0.23 | -0.17 | 0.48 | -0.06 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 256.95 | 47.67 | 47.78 | 77.64 | 90.68 | 72.92 | 179.07 | 225.63 | 96.21 | 68.98 | 99.97 | 96.05 |
Inventory Days | 261.72 | 13.98 | 80.49 | 11.77 | 55.86 | 43.40 | 134.51 | 124.67 | 65.84 | 111.66 | 103.36 | 126.07 |
Days Payable | 1,692.02 | 57.90 | 184.68 | 216.27 | 292.87 | 249.28 | 403.08 | 374.43 | 166.48 | 214.10 | 268.79 | 297.81 |
Cash Conversion Cycle | -1,173.34 | 3.74 | -56.42 | -126.86 | -146.33 | -132.96 | -89.49 | -24.13 | -4.43 | -33.46 | -65.47 | -75.69 |
Working Capital Days | -93.82 | -71.75 | -79.23 | -64.04 | -43.05 | -33.67 | -10.35 | 7.33 | 8.11 | -16.87 | -37.41 | -41.05 |
ROCE % | 3.13% | 6.15% | 2.52% | 1.99% | 2.36% | 6.01% | 6.65% | 7.55% | 3.60% | -12.09% | -12.00% | -4.65% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 24h
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Nov - Copy of newspaper advertisement published on November 06, 2024 regarding unaudited financial results for the Quarter and Half Yearly ended September 30, 2024 as published …
-
Approval Of Un-Audited Financial Results For The Quarter And Half Yearly Ended September 30, 2024
5 Nov - Approval of un-audited financial results for Q2 2024.
-
Board Meeting Outcome for The Outcome Of Meeting Of The Board Of Phaarmasia Limited Held On Tuesday, November 05, 2024; Commenced At 02:30 P.M. And Ended At 05:30 P.M
5 Nov - Outcome of Board Meeting discussing financial statements.
-
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On November 05, 2024 To Consider Unaudited Financial Results For The Quarter And Half Yearly Ended September 30, 2024.
31 Oct - Board meeting to discuss Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company provides various therapeutic dosage combinations for Ministry of Health & Family Welfare and also for exports. In FY20, company became a Sick Industrial Company under SICA and was referred to BIFR.